Skip to main content

These studies are designed to investigate ways of preventing HIV acquisition.

 

HPTN 083 Logo

HPTN 083 – Give PrEP a Shot

Goal Assessing the safety and efficacy of cabotegravir, an investigational, long-acting, injectable HIV medication, versus Truvada, the only FDA-approved medication for HIV prevention.
Who is eligible to participate Men who have sex with other men or transgender women (born male) who are older than 18 years of age and in generally good health.
Medication Injectible Cabotegravir & Truvada (also known as PrEP)
Duration 4.5 years
Compensation